Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › atrial flutter

Atrial flutter

Part of Cardiac arrhythmias

Subtypes of Atrial flutter

Typical atrial flutter 1

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for atrial flutter

26 trials tracked for atrial flutter: 9 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

26Trials tracked
9Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 6 Phase 3 3 Phase 2 3 Other / NA 14
  1. Phase 4 Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion Completed · 4 cited
  2. Phase 4 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Completed
  3. Phase 4 Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation Completed
  4. Phase 4 Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8) Completed
  5. Phase 4 Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter Completed
  6. Phase 4 Concentrations of Amiodarone in Fat Tissue During Chronic Treatment Completed
Show 20 more trials
  1. Phase 3 Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery Completed
  2. Phase 3 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation Completed
  3. Phase 3 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed
  4. Phase 2 Cardiac Electrophysiological Study Completed
  5. Phase 2 Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm Completed
  6. Phase 2 Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed
  7. N/A Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter Completed
  8. N/A iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology Completed
  9. N/A An Initial Assessment of the Sphere-9™ Catheter and Affera Mapping and Ablation System Completed
  10. N/A FREEZE-AFIB Post-Market Study Completed
  11. N/A Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias Completed
  12. N/A Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias Completed
  13. N/A Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation Completed
  14. N/A Assessment of the Sphere-9™ Catheter and Affera Mapping and Ablation System for Treatment of Atrial and Ventricular Arrhythmias Completed
  15. N/A Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies Completed
  16. N/A Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus Completed
  17. N/A ArcticLine Feasibility Study Completed
  18. N/A Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial Completed
  19. N/A Wire Instrumentation Using Radiofrequency Energy to Impact Transseptal Efficiency Completed
  20. N/A Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Atrial flutter: what the trials found

Pharmacological management of atrial flutter includes various agents. Dronedarone was associated with a lower rate of first hospitalization for cardiovascular reasons or death from any cause compared to the control group (p<0.0001) 9. While dronedarone showed a significant reduction in hospitalizations, the difference in total deaths from any cause did not reach statistical significance (p=0.18) 9. Warfarin was evaluated for stroke and bleeding; it demonstrated significantly lower rates of adjudicated stroke or systemic embolism (p=0.0114) and significantly lower rates of major bleed events (p<0.0001) compared to the comparison group, while all-cause death rates were also significantly lower (p=0.0465) 8.

Interventional procedures for atrial flutter show high efficacy in achieving conduction block and success rates. RF energy delivery for typical atrial flutter resulted in a 93.3% rate of complete bidirectional conduction block (p=0.05) with a low incidence of cardiovascular-specific adverse events within seven days (1.5%, p=0.05) 4. The use of a gold tip catheter showed significant success with the first catheter (p=0.042), though duration of energy application did not differ significantly between groups (p=0.25) 5. Long-term treatment success was observed in patients treated with gold tip catheters, showing no statistically significant difference between groups (p=0.53) 5.

Other established interventions and technologies include the use of propofol 1, beta blockers 7, dabigatran etexilate mesylate 3, fat tissue needle aspiration 6, and specialized mapping systems such as the Sphere-9 Catheter and Affera Mapping and Ablation System, which reported a 19% rate of subjects free from documented recurrence 14.

Recent results — preliminary, needs further review

  • Amiodarone weight-based dosing showed specific steady-state concentrations (p-values not provided) 10.
  • AliveCor technology was associated with lower rates of atrial arrhythmia recurrence and shorter time to treatment for recurrence compared to the control group (p=0.05) 16.
  • ArcticLine Cardiac Cryoablation Catheter showed zero primary safety events within 7 days post-procedure 20.

For the clinician treating this condition

  • Dronedarone significantly reduces the risk of hospitalization for cardiovascular reasons or death compared to standard care 9.
  • Warfarin is associated with lower rates of stroke, systemic embolism, and major bleeding in patients undergoing treatment 8.
  • RF energy delivery for typical atrial flutter achieves a high rate of complete bidirectional conduction block (93.3%) with low early adverse events 4.

AI synthesis of 12 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Inadequate sleep duration is associated with higher risk of atrial flutter recurrence after ablation
Cardiology RCT
Inadequate sleep duration is associated with higher risk of atrial flutter recurrence after ablation Short or long sleep may increase risk of heart rhythm issues
This multicentre randomized controlled trial of 720 patients undergoing catheter ablation for atrial fibrillation found no significant assoc…
Patients with atrial fibrillation who get less than 6 hours or more than 8 hours of sleep face a higher risk of specific heart rhythm recurr…
medRxiv Jul 14, 2026
Fragmented QRS is associated with a 2.11 risk ratio for post-ablation atrial tachyarrhythmia
Cardiology Meta-analysis
Fragmented QRS is associated with a 2.11 risk ratio for post-ablation atrial tachyarrhythmia Fragmented QRS Signals Linked to Higher Risk After Heart Surgery
This meta-analysis of six cohort studies evaluates the association between fragmented QRS (fQRS) and post-ablation outcomes in patients with…
A specific heart signal called fragmented QRS may help doctors identify patients at higher risk for recurring heart rhythm issues after surg…
Jul 1, 2026
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
Cardiology Sys. Review
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Frontiers Jun 9, 2026
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation
Cardiology RCT
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation PFA Ablation Matches Old Method With Less Time
This substudy RCT compared bipolar linear pulsed field ablation (PFA) with irrigated radiofrequency ablation (RFA) in 141 patients with pers…
Doctors can treat a specific heart rhythm problem faster with new technology without making it less safe.
Apr 16, 2026

Research across Cardiac arrhythmias

Related studies from across the Cardiac arrhythmias family.

Edoxaban patients with CAD/PAD show higher stroke, ACS, and cardiovascular death rates
Cardiology RCT
Edoxaban patients with CAD/PAD show higher stroke, ACS, and cardiovascular death rates Patients with heart disease face higher risks on edoxaban
This prospective cohort study of 13,164 patients with atrial fibrillation (AF) receiving edoxaban in routine care found significantly higher…
New data shows that patients with atrial fibrillation and existing heart disease may face higher rates of stroke and bleeding while on edoxa…
Aug 9, 2026
DOAC plus calcium-channel blocker co-use raises major bleeding risk 21% in atrial fibrillation
Cardiology Meta-analysis
DOAC plus calcium-channel blocker co-use raises major bleeding risk 21% in atrial fibrillation Combining certain heart medications may increase risk of major bleeding
This meta-analysis of 408,276 patients with atrial fibrillation and elevated thromboembolic risk found that co-use of direct oral anticoagul…
Patients with atrial fibrillation taking both a specific blood thinner and a calcium channel blocker may face a higher risk of serious bleed…
Aug 9, 2026
No difference in cardioversion success between RBW and BTE waveforms for atrial fibrillation
Cardiology RCT
No difference in cardioversion success between RBW and BTE waveforms for atrial fibrillation Trial Shows No Difference Between Two Shock Waveforms for Atrial Fibrillation
This randomized trial of 546 adult patients with symptomatic atrial fibrillation found no significant difference in successful direct curren…
A clinical trial found that two different types of electrical shock waveforms are equally effective at treating atrial fibrillation.
Aug 9, 2026
CHAT-AF-S conversational AI protocol aims to improve quality of life in atrial fibrillation
Cardiology RCT
CHAT-AF-S conversational AI protocol aims to improve quality of life in atrial fibrillation Trial Plans to Test AI Chatbots for Atrial Fibrillation Patients
This randomised controlled trial protocol will enroll 480 adults with atrial fibrillation to test whether a conversational AI self-managemen…
A new clinical trial plans to see if conversational artificial intelligence can improve the quality of life for adults living with atrial fi…
Aug 9, 2026
AI-enabled devices with nurse-led screening show good diagnostic accuracy for opportunistic atrial fibrillation detection
Cardiology Sys. Review
AI-enabled devices with nurse-led screening show good diagnostic accuracy for opportunistic atrial fibrillation detection AI tools and nurses help find heart rhythm problems early
This mini review explores the use of AI-enabled single-lead ECG and photoplethysmography for atrial fibrillation screening by non-physician …
New screening methods using AI and nurse-led checkups could catch atrial fibrillation sooner to lower stroke risks in community settings.
Frontiers Aug 9, 2026
Perioperative dexmedetomidine reduces postoperative atrial fibrillation and delirium risk in adult cardiac surgery patients
Cardiology Meta-analysis
Perioperative dexmedetomidine reduces postoperative atrial fibrillation and delirium risk in adult cardiac surgery patients Dexmedetomidine May Lower Risk of Heart Rhythms and Delirium
This meta-analysis of randomized controlled trials involving 4063 patients found that perioperative dexmedetomidine significantly reduced th…
A new review suggests that dexmedetomidine may lower the risk of heart rhythm issues and delirium for adults undergoing cardiac surgery.
Aug 8, 2026
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents
Cardiology RCT
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents NOAC Monotherapy Shows Lower Risk for Older Patients with Atrial Fibrillation
This post hoc analysis investigated the impact of NOAC monotherapy versus combination therapy with clopidogrel in patients with atrial fibri…
Patients over 75 with atrial fibrillation and drug-eluting stents may have fewer adverse events when taking a single NOAC instead of combina…
Aug 5, 2026
CCTA imaging biomarkers provide multidimensional cardiovascular risk stratification for coronary heart disease and atrial fibrillation
Cardiology Meta-analysis
CCTA imaging biomarkers provide multidimensional cardiovascular risk stratification for coronary heart disease and atrial fibrillation New imaging markers help identify high risk heart disease
This narrative review synthesizes evidence on CCTA imaging biomarkers, including plaque characteristics, FFR-CT, EAT, PCAT, and hepatic stea…
Advanced imaging can now spot specific signs of heart inflammation and plaque growth to better predict serious heart events.
Frontiers Aug 5, 2026
Thromboembolic events cost 2.5-fold more per event than bleeding after high-risk endoscopy
Gastroenterology RCT
Thromboembolic events cost 2.5-fold more per event than bleeding after high-risk endoscopy High Risk Endoscopy Procedures Linked to Bleeding in Patients
This retrospective cohort study of 2,486 adults on DOAC or warfarin undergoing high-risk endoscopy found a 22.9% bleeding rate at 90 days an…
Patients with atrial fibrillation undergoing high-risk endoscopy face significant risks of bleeding and stroke, which can lead to high medic…
medRxiv Aug 4, 2026
Impact of Infarct Volume on Safety and Efficacy of Early DOAC Initiation
Cardiology RCT
Impact of Infarct Volume on Safety and Efficacy of Early DOAC Initiation Trial shows early blood thinners help stroke patients with heart issues
This large-scale trial confirms that early DOAC initiation remains safe and effective regardless of the initial ischemic stroke infarct size…
Early use of blood thinners after a stroke may improve outcomes for patients with atrial fibrillation, regardless of the size of the brain i…
Aug 3, 2026
Evaluating Safety and Efficacy of Shortened Dual Antithrombotic Therapy in Atrial Fibrillation
Cardiology RCT
Evaluating Safety and Efficacy of Shortened Dual Antithrombotic Therapy in Atrial Fibrillation Short dual therapy may reduce bleeding for heart patients
A randomized trial demonstrates that a 1-month dual therapy period significantly reduces bleeding risks without compromising efficacy.
A new trial suggests that a shorter period of dual blood thinners can lower bleeding risks for patients with atrial fibrillation and heart i…
Aug 2, 2026
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism
Cardiology Meta-analysis
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism Direct oral anticoagulants show promise for patients with liver cirrhosis
A meta-analysis of predominantly observational studies compared direct oral anticoagulants with traditional anticoagulants in patients with …
New analysis suggests direct oral anticoagulants may reduce blood clots and major bleeding risks for patients with liver cirrhosis and heart…
Aug 1, 2026